

# RETISERT- fluocinolone acetonide implant

## Bausch & Lomb Incorporated

-----

### HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use RETISERT safely and effectively. See full prescribing information for RETISERT.

**RETISERT (fluocinolone acetonide intravitreal implant) 0.59 mg,  
for intravitreal use  
Initial U.S. Approval: 1963**

### INDICATIONS AND USAGE

RETISERT is a corticosteroid indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. (1)

### DOSAGE AND ADMINISTRATION

- RETISERT is surgically implanted into the posterior segment of the affected eye through a pars plana incision. (2.1)
- RETISERT is designed to release fluocinolone acetonide at a nominal initial rate of 0.6 mcg/day, decreasing over the first month to a steady state between 0.3-0.4 mcg/day over approximately 30 months. (2.1)
- Aseptic technique should be maintained at all times prior to and during the surgical implantation procedure. (2.2)

### DOSAGE FORMS AND STRENGTHS

1. 0.59 mg fluocinolone acetonide intravitreal implant. (3)

### CONTRAINDICATIONS

1. Surgical placement of RETISERT is contraindicated in active viral, bacterial, mycobacterial and fungal infections of ocular structures. (4.1)

### WARNINGS AND PRECAUTIONS

- Cataract formation: Nearly all phakic patients are expected to develop cataracts and require cataract surgery. (5.1)
- Endophthalmitis: Late onset endophthalmitis has been observed. (5.2)
- Increase in intraocular pressure: Use of corticosteroids may result in elevated IOP and/or glaucoma. (5.3) IOP lowering medications were required in > 75% of patients; filtering surgeries were required in > 35% of patients. (6.1)
- Separation of implant components: Physicians should periodically monitor the integrity of the implant by visual inspection. (5.4)

### ADVERSE REACTIONS

- Ocular adverse events included procedural complications, and eye pain (> 50%). Thirty-five to forty percent of patients reported ocular/conjunctival hyperemia, reduced visual acuity, and conjunctival hemorrhage. (6.1)
- The most common non-ocular event reported was headache (33%). (6.2)

**To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).  
See 17 for PATIENT COUNSELING INFORMATION.**

Revised: 4/2025

## **2 DOSAGE AND ADMINISTRATION**

2.1 Dosing Information

2.2 Handling of Implant

## **3 DOSAGE FORMS AND STRENGTHS**

## **4 CONTRAINDICATIONS**

4.1 Viral, Bacterial, Mycobacterial and Fungal Infections of Ocular Structures

## **5 WARNINGS AND PRECAUTIONS**

5.1 Cataract Formation

5.2 Endophthalmitis and Surgical Complications

5.3 Increase in Intraocular Pressure

5.4 Separation of Implant Components

5.5 Other Corticosteroid Induced Adverse Reactions

## **6 ADVERSE REACTIONS**

6.1 Clinical Trials Experience - Ocular Events

6.2 Clinical Trials Experience - Non-Ocular Events

## **8 USE IN SPECIFIC POPULATIONS**

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

## **11 DESCRIPTION**

## **12 CLINICAL PHARMACOLOGY**

12.1 Mechanism of Action

12.3 Pharmacokinetics

## **13 NONCLINICAL TOXICOLOGY**

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

## **14 CLINICAL STUDIES**

## **16 HOW SUPPLIED/STORAGE AND HANDLING**

## **17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed.

---

## **FULL PRESCRIBING INFORMATION**

### **1 INDICATIONS AND USAGE**

RETISERT<sup>®</sup> is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

### **2 DOSAGE AND ADMINISTRATION**

#### **2.1 Dosing Information**

RETISERT is implanted into the posterior segment of the affected eye through a pars plana incision.

The implant contains one tablet of 0.59 mg of fluocinolone acetonide. RETISERT is

designed to release fluocinolone acetonide at a nominal initial rate of 0.6 mcg/day, decreasing over the first month to a steady state between

0.3-0.4 mcg/day over approximately 30 months. Following depletion of fluocinolone acetonide as evidenced by recurrence of uveitis, RETISERT may be replaced.

## **2.2 Handling of Implant**

Caution should be exercised in handling RETISERT in order to avoid damage to the implant, which may result in an increased rate of drug release from the implant. Thus, RETISERT should be handled only by the suture tab. Care should be taken during implantation and explantation to avoid shear forces on the implant that could disengage the silicone cup reservoir (which contains a fluocinolone acetonide tablet) from the suture tab. Aseptic technique should be maintained at all times prior to and during the surgical implantation procedure.

RETISERT should not be resterilized by any method.

## **3 DOSAGE FORMS AND STRENGTHS**

0.59 mg fluocinolone acetonide intravitreal implant.

## **4 CONTRAINDICATIONS**

### **4.1 Viral, Bacterial, Mycobacterial and Fungal Infections of Ocular Structures**

Surgical placement of RETISERT is contraindicated in active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in active bacterial, mycobacterial or fungal infections of the eye.

## **5 WARNINGS AND PRECAUTIONS**

### **5.1 Cataract Formation**

Use of corticosteroids may result in posterior subcapsular cataract formation. Based on clinical trials with RETISERT, during the 3-year post-implantation period, nearly all phakic eyes are expected to develop cataracts and require cataract surgery.

### **5.2 Endophthalmitis and Surgical Complications**

Late onset endophthalmitis has been observed. These events are often related to the integrity of the surgical wound site. Careful attention to assure tight closure of the scleral wound and the integrity of the overlying conjunctiva at the wound site is important.

Potential complications accompanying intraocular surgery to place RETISERT into the vitreous cavity may include, but are not limited to, the following: cataract formation, choroidal detachment, endophthalmitis, hypotony, increased intraocular pressure, exacerbation of intraocular inflammation, retinal detachment, vitreous hemorrhage, vitreous loss, and wound dehiscence.

Following implantation of RETISERT, nearly all patients will experience an immediate and

temporary decrease in visual acuity in the implanted eye which lasts for approximately one to four weeks post-operatively.

### **5.3 Increase in Intraocular Pressure**

Prolonged use of corticosteroids may result in elevated IOP and/or glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Patients must be monitored for elevated IOP.

Based on clinical trials with RETISERT, within 3-years post-implantation, approximately 77% of patients will require IOP lowering medications to control intraocular pressure and 37% of patients will require filtering procedures to control intraocular pressure [see *Adverse Reactions ( 6.1)*].

### **5.4 Separation of Implant Components**

In vitro stability studies show that the strength of the adhesive bond between the silicone cup reservoir and the suture tab is reduced with prolonged hydration, indicating a potential for the separation of these components. The suture tab composition is a silicone elastomer reinforced with a polyester mesh. Physicians should periodically monitor the integrity of the implant by visual inspection.

### **5.5 Other Corticosteroid Induced Adverse Reactions**

RETISERT should be used with caution in patients with a history of a viral, bacterial, mycobacterial or fungal infection of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia and varicella. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution.

Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections (bacterial, fungal, and viral). In acute purulent conditions of the eye, steroids may mask infection or enhance existing infection. Fungal and viral infections of the cornea are particularly prone to develop coincidentally with long-term application of steroids. The possibility of fungal invasion should be considered in any persistent corneal ulceration where steroid treatment has been used.

Since resistance to infections is known to be reduced by corticosteroids, simultaneous bilateral implantation should not be carried out, in order to limit the potential for bilateral post-operative infection.

Ocular administration of corticosteroids has also been associated with delayed wound healing and perforation of the globe where there is thinning of the sclera.

The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.

## **6 ADVERSE REACTIONS**

### **6.1 Clinical Trials Experience - Ocular Events**

The available safety data includes exposure to RETISERT in patients with chronic non-infectious uveitis affecting the posterior segment in two multicenter controlled clinical trials. Patients were randomized to dosage regimens of 0.59 mg or 2.1 mg implants.

The most frequently reported ocular adverse events were cataract, increased intraocular pressure, procedural complication, and eye pain. These events occurred in approximately 50 - 90% of patients. Cataract includes aggravated cataract, and posterior capsular opacification. Procedural complications includes post-op complication, post-op wound complication, post-op wound site erythema, and wound dehiscence.

Based on clinical trials with RETISERT, during the 3-year post-implantation period, nearly all phakic eyes are expected to develop cataracts and require cataract surgery. IOP lowering medications to lower intraocular pressure were required in approximately 77% of patients; filtering surgeries were required to control intraocular pressure in 37% of patients. Ocular adverse events occurring in approximately 10 - 40% of patients in decreasing order of incidence were ocular/conjunctival hyperemia, reduced visual acuity, glaucoma, conjunctival hemorrhage, blurred vision, abnormal sensation in the eye, eye irritation, maculopathy, vitreous floaters, hypotony, pruritus, ptosis, increased tearing, vitreous hemorrhage, dry eye, eyelid edema, macular edema and visual disturbance.

Ocular adverse events occurring in approximately 5 - 9% of patients in decreasing order of incidence were eye discharge, photophobia, blepharitis, corneal edema, iris adhesions, choroidal detachment, diplopia, eye swelling, retinal detachment, photopsia, retinal hemorrhage and hyphema.

## **6.2 Clinical Trials Experience - Non-Ocular Events**

The most frequently reported non-ocular adverse event was headache (33%). Other non-ocular adverse events occurring in approximately 5-20% of patients in decreasing order of incidence were nasopharyngitis, arthralgia, sinusitis, dizziness, pyrexia, upper respiratory tract infection, influenza, vomiting, nausea, cough, back pain, limb pain, and rash.

## **8 USE IN SPECIFIC POPULATIONS**

### **8.1 Pregnancy**

#### Risk Summary

Adequate and well-controlled studies with RETISERT have not been conducted in pregnant women to inform drug-associated risk. Animal reproduction studies have not been conducted with RETISERT. It is not known whether RETISERT can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.

Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. RETISERT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

### **8.2 Lactation**

## Risk Summary

There are no data on the presence of RETISERT in human milk, the effects on the breastfed infant, or the effects on milk production. Systemically administered corticosteroids are present in human milk and can suppress growth, interfere with endogenous corticosteroid production, or cause other unwanted effects. Clinical or nonclinical lactation studies have not been conducted with RETISERT.

It is not known whether intravitreal treatment with RETISERT could result in sufficient systemic absorption to produce detectable quantities of fluocinolone acetonide in human milk, or affect breastfed infants or milk production.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for RETISERT and any potential adverse effects on the breastfed child from RETISERT or from the underlying maternal condition.

### **8.4 Pediatric Use**


Safety and effectiveness in pediatric patients below the age of 12 years have not been established.

### **8.5 Geriatric Use**

No overall differences in safety and effectiveness have been observed between elderly and younger patients.

## **11 DESCRIPTION**

RETISERT<sup>®</sup> (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 mcg/day, decreasing over the first month to a steady state between 0.3-0.4 mcg/day over approximately 30 months. The drug substance is the synthetic corticosteroid fluocinolone acetonide, represented by the following structural formula:



$C_{24}H_{30}F_2O_6$  Mol. Wt. 452.50

Chemical Name: Pregna-1,4-diene-3,20-dione,6,9-difluoro-11,21-dihydroxy-16,17-[(1-methyl-ethylidene)bis(oxy)],(6 $\alpha$ ,11 $\beta$ ,16 $\alpha$ )-.

Fluocinolone acetonide is a white crystalline powder, insoluble in water, and soluble in methanol. It has a melting point of 265-266°C.

Each RETISERT consists of a tablet containing 0.59 mg of the active ingredient, Fluocinolone Acetonide, USP, and the following inactives: magnesium stearate, microcrystalline cellulose, and polyvinyl alcohol.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.

There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A<sub>2</sub> inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A<sub>2</sub>. Corticosteroids are capable of producing a rise in intraocular

pressure.

### 12.3 Pharmacokinetics

In a subset of patients who received the intravitreal implant, and had blood samples taken at various times (weeks 1, 4 and 34) after implantation, plasma levels of fluocinolone acetonide were below the limit of detection (0.2 ng/mL) at all times. Aqueous and vitreous humor samples were assayed for fluocinolone acetonide in a further subset of patients. While detectable concentrations of fluocinolone acetonide were seen throughout the observation interval (up to 34 months), the concentrations were highly variable, ranging from below the limit of detection (0.2 ng/mL) to 589 ng/mL.

## 13 NONCLINICAL TOXICOLOGY

### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term animal studies have not been performed to determine the carcinogenic potential or the effect on fertility of RETISERT.

Fluocinolone acetonide was not genotoxic *in vitro* in the Ames test (*S. typhimurium* and *E. coli*), the mouse lymphoma TK assay, or *in vivo* in the mouse bone marrow micronucleus assay.

## 14 CLINICAL STUDIES

In two randomized, double-masked, multicenter controlled clinical trials, 224 patients with chronic (a one year or greater history) non-infectious uveitis affecting the posterior segment of one or both eyes were randomized to receive a 0.59 mg RETISERT. The primary efficacy endpoint in both trials was the rate of recurrence of uveitis affecting the posterior segment of the study eye in the 34 week pre-implantation period compared to the rate of recurrence in the 34 week post-implantation period. Uveitis recurrence rates at 1, 2, and 3 year post-implantation were also compared to the 34 week pre-implantation period.

Detailed results are shown in Table 1 below:

**Table 1: Uveitis Recurrence Rates**

TIME POINT	STUDY 1	STUDY 2
	N=108	N=116
	Uveitis Recurrence Rates <sup>1,2</sup> N (%)	
34 Weeks Pre-implantation	58 (53.7)	46 (39.7)
34 Weeks Post-implantation	2 (1.8)	15 (12.9)
1 Year Post-implantation	4 (3.7)	15 (12.9)
2 Years Post-implantation	11 (10.2)	16 (13.8)
3 Years Post-implantation	22 (20.4)	20 (17.2)

3 Weeks Post-implantation	33 (30.6)	28 (24.1)
---------------------------	-----------	-----------

<sup>1</sup>Recurrence of uveitis for all post-implantation time points was compared to the 34 weeks pre-implantation time point.

<sup>2</sup>p-value <0.01 from McNemar's  $\chi^2$  test.

<sup>3</sup>Results presented include imputed recurrences. Recurrences were imputed when a subject was not seen within 10 weeks of their final scheduled visit.

In assessing the effect of RETISERT on the corneal endothelial cell density in eyes that have been implanted for a minimum of 1 year, the results indicate that eyes containing the RETISERT implant for an average of 3.54 years had a lower mean corneal endothelial cell density (mean paired difference of -435 cells/mm<sup>2</sup>) compared with non-implanted eyes (p<0.01).

## 16 HOW SUPPLIED/STORAGE AND HANDLING

The implant consists of a tablet encased in a silicone elastomer cup containing a release orifice and a polyvinyl alcohol membrane positioned between the tablet and the orifice. The silicone elastomer cup assembly is attached to a silicone elastomer suture tab with silicone adhesive. Each RETISERT is approximately 3 mm x 2 mm x 5 mm.

Each implant is stored in a clear polycarbonate case within a foil pouch within a Tyvek peelable overwrap. Each packaged implant is provided in a carton which includes the package insert.

NDC 24208-416-01 0.59 mg 1 count

**Storage:** Store in the original container at 15°C to 25°C (59°F to 77°F). **Protect from freezing.**

## 17 PATIENT COUNSELING INFORMATION

Patients should be advised to have ophthalmologic follow-up examinations of both eyes at appropriate intervals following implantation of RETISERT.

As with any surgical procedure, there is risk involved. Potential complications accompanying intraocular surgery to place RETISERT into the vitreous cavity may include, but are not limited to, the following: cataract formation, choroidal detachment, temporary decreased visual acuity, endophthalmitis, hypotony, increased intraocular pressure, exacerbation of intraocular inflammation, retinal detachment, vitreous hemorrhage, vitreous loss, and wound dehiscence.

Following implantation of RETISERT, nearly all patients will experience an immediate and temporary decrease in visual acuity in the implanted eye which lasts for approximately one to four weeks post-operatively.

Based on clinical trials with RETISERT, within 3 years post-implantation, approximately 77% of patients will require IOP lowering medications to control intraocular pressure and 37% of patients will require filtering procedures to control intraocular pressure [see *Adverse Reactions* ( [6.1](#))] .

Based on clinical trials with RETISERT, during the 3-year post-implantation period, nearly all phakic eyes are expected to develop cataracts and require cataract surgery.

**Manufactured for:**

Bausch & Lomb Americas Inc  
Bridgewater, NJ 08807 USA

**Manufactured by:**

Bausch + Lomb Ireland Limited  
Waterford, Ireland

RETISERT is a trademark of Bausch & Lomb Incorporated or its affiliates.

© 2025 Bausch & Lomb Incorporated or its affiliates

9028012

**PACKAGE/LABEL PRINCIPAL DISPLAY PANEL**



NDC24208-416-01

**Rx only**

**Retisert<sup>®</sup>**

**(fluocinolone acetonide**

**intravitreal implant) 0.59 mg**

**STERILE**

**FOR INTRAVITREAL IMPLANTATION ONLY**

**Contents:**One sterile Retisert<sup>®</sup> (fluocinolone acetonide intravitreal implant)  
0.59 mg

Content sterile in unopened, undamaged package.

**BAUSCH + LOMB**

<b>RETISERT</b>				
fluocinolone acetonide implant				
<b>Product Information</b>				
<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:24208-416	
<b>Route of Administration</b>	INTRAVITREAL			
<b>Active Ingredient/Active Moiety</b>				
	<b>Ingredient Name</b>	<b>Basis of Strength</b>	<b>Strength</b>	
	<b>FLUOCINOLONE ACETONIDE</b> (UNII: 0CD5FD6S2M) (FLUOCINOLONE ACETONIDE - UNII:0CD5FD6S2M)	FLUOCINOLONE ACETONIDE	0.59 mg	
<b>Inactive Ingredients</b>				
	<b>Ingredient Name</b>		<b>Strength</b>	
	<b>MAGNESIUM STEARATE</b> (UNII: 70097M6I30)			
	<b>MICROCRYSTALLINE CELLULOSE</b> (UNII: OP1R32D61U)			
	<b>POLYVINYL ALCOHOL, UNSPECIFIED</b> (UNII: 532B59J990)			
<b>Packaging</b>				
<b>#</b>	<b>Item Code</b>	<b>Package Description</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>
1	NDC:24208-416-01	1 in 1 CARTON	04/08/2005	
1		1 in 1 POUCH; Type 0: Not a Combination Product		
<b>Marketing Information</b>				
<b>Marketing Category</b>	<b>Application Number or Monograph Citation</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>	

NDA	NDA021737	04/08/2005	
-----	-----------	------------	--

**Labeler** - Bausch & Lomb Incorporated (196603781)

## Establishment

Name	Address	ID/FEI	Business Operations
Bausch and Lomb Ireland Limited		986019757	manufacture(24208-416) , pack(24208-416) , label(24208-416)

Revised: 4/2025

Bausch & Lomb Incorporated